Geron/$GERN
1D1W1MYTD1Y5YMAX
About Geron
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.
- Ticker
- $GERN
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 258
- Headquarters
- Foster City, United States
- Website
- www.geron.com
Geron Metrics
BasicAdvanced
$970M
-
-$0.10
0.59
-
Price and volume
Market cap
$970M
Beta
0.59
52-week high
$2.01
52-week low
$1.04
Average daily volume
10M
Financial strength
Current ratio
6.915
Quick ratio
5.038
Long term debt to equity
55.409
Total debt to equity
55.872
Interest coverage (TTM)
-1.17%
Profitability
EBITDA (TTM)
-34.799
Gross margin (TTM)
58.50%
Net profit margin (TTM)
-33.05%
Operating margin (TTM)
-17.25%
Revenue per employee (TTM)
$790,000
Management effectiveness
Return on assets (TTM)
-4.11%
Return on equity (TTM)
-28.28%
Valuation
Price to revenue (TTM)
4.936
Price to book
4.44
Price to tangible book (TTM)
4.44
Price to free cash flow (TTM)
-8.798
Free cash flow yield (TTM)
-11.37%
Free cash flow per share (TTM)
-0.172
Growth
Revenue change (TTM)
24.39%
Earnings per share change (TTM)
-23.63%
3-year revenue growth (CAGR)
668.90%
10-year revenue growth (CAGR)
18.80%
3-year earnings per share growth (CAGR)
-34.58%
10-year earnings per share growth (CAGR)
29.57%
What the Analysts think about Geron
Analyst ratings (Buy, Hold, Sell) for Geron stock.
Geron Financial Performance
Revenues and expenses
Geron Earnings Performance
Company profitability
Geron News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.